Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 116

1.

Practice patterns of Korean urologists for screening and managing prostate cancer according to PSA level.

Chung MS, Lee SH, Lee DH, Kim SJ, Kim CS, Lee KS, Jung JI, Kim SW, Lee YS, Chung BH.

Yonsei Med J. 2012 Nov 1;53(6):1136-41. doi: 10.3349/ymj.2012.53.6.1136.

2.

Use of low free to total PSA ratio in prostate cancer screening: detection rates, clinical and pathological findings in Brazilian men with serum PSA levels <4.0 ng/mL.

Faria EF, Carvalhal GF, dos Reis RB, Tobias-Machado M, Vieira RA, Reis LO, Nogueira L, Machado RD, Freitas CH Jr, Magnabosco WJ, Mauad EC, Carvalho AL.

BJU Int. 2012 Dec;110(11 Pt B):E653-7. doi: 10.1111/j.1464-410X.2012.11398.x. Epub 2012 Aug 14.

3.

Detection rate of prostate cancer on biopsy according to serum prostate-specific antigen in Korean men: a multicenter study.

Yang WJ, Lee DH, Chung BH, Cho JS, Choi YD, Kim SJ, Cho IR, Kim HS, Kim CI, Hong SJ; Members of the Severance Urologic Oncology Group.

Urology. 2006 Feb;67(2):333-6.

PMID:
16461083
4.

Prostate-specific antigen-based early detection of prostate cancer--validation of screening without rectal examination.

Schröder FH, Roobol-Bouts M, Vis AN, van der Kwast T, Kranse R.

Urology. 2001 Jan;57(1):83-90.

PMID:
11164149
5.

Practice patterns of urologists in managing Korean men aged 40 years or younger with high serum prostate-specific antigen levels.

Yoo DS, Woo SH, Cho S, Kang SH, Kim SJ, Park SY, Lee SH, Jeon SH, Park J.

Urology. 2014 Jun;83(6):1339-43. doi: 10.1016/j.urology.2014.02.014. Epub 2014 Apr 13.

PMID:
24726151
6.

[Clinical value of prostate specific antigen screening in early detection of prostate cancer].

Hua LX, Qiao D, Song NH, Feng NH, Yang J, Zhang JX, Chen JG, Zhang W, Sui YG, Wu HF.

Zhonghua Zhong Liu Za Zhi. 2009 Sep;31(9):705-9. Chinese.

PMID:
20021870
7.

Prostate cancer screening in the Tyrol, Austria: experience and results.

Horninger W, Reissigl A, Rogatsch H, Volgger H, Studen M, Klocker H, Bartsch G.

Eur J Cancer. 2000 Jun;36(10):1322-35. Retraction in: Eur J Cancer. 2012 Jan;48(2):286.

PMID:
10882875
8.

Distribution of serum prostate-specific antigen in healthy Korean men: influence of ethnicity.

Ku JH, Ahn JO, Lee CH, Lee NK, Park YH, Byun SS, Kwak C, Lee SE.

Urology. 2002 Sep;60(3):475-9.

PMID:
12350489
9.

Detection rates and biologic significance of prostate cancer with PSA less than 4.0 ng/mL: observation and clinical implications from Tyrol screening project.

Pelzer AE, Tewari A, Bektic J, Berger AP, Frauscher F, Bartsch G, Horninger W.

Urology. 2005 Nov;66(5):1029-33.

PMID:
16286118
10.
11.

Prostate volume as an independent predictor of prostate cancer in men with PSA of 10-50 ng ml(-1).

Tang P, Jin XL, Uhlman M, Lin YR, Deng XR, Wang B, Xie KJ.

Asian J Androl. 2013 May;15(3):409-12. doi: 10.1038/aja.2013.11. Epub 2013 Apr 8.

12.

Lowering the PSA threshold for prostate biopsy from 4 to 2.5 ng/ml: influence on cancer characteristics and number of men needed to biopt.

Müntener M, Kunz U, Eichler K, Puhan M, Schmid DM, Sulser T, Strebel RT.

Urol Int. 2010;84(2):141-6. doi: 10.1159/000277589. Epub 2010 Mar 4.

13.

Inverse association between histologic inflammation in needle biopsy specimens and prostate cancer in men with serum PSA of 10-50 ng/mL.

Terakawa T, Miyake H, Kanomata N, Kumano M, Takenaka A, Fujisawao M.

Urology. 2008 Dec;72(6):1194-7. doi: 10.1016/j.urology.2008.07.028. Epub 2008 Oct 1.

PMID:
18829081
14.

Complexed prostate-specific antigen for early detection of prostate cancer in men with serum prostate-specific antigen levels of 2 to 4 nanograms per milliliter.

Horninger W, Cheli CD, Babaian RJ, Fritsche HA, Lepor H, Taneja SS, Childs S, Stamey TA, Sokoll LJ, Chan DW, Brawer MK, Partin AW, Bartsch G.

Urology. 2002 Oct;60(4 Suppl 1):31-5.

PMID:
12384160
15.

Prostate cancer in Korean men exhibits poor differentiation and is adversely related to prognosis after radical prostatectomy.

Song C, Ro JY, Lee MS, Hong SJ, Chung BH, Choi HY, Lee SE, Lee E, Kim CS, Ahn H.

Urology. 2006 Oct;68(4):820-4.

PMID:
17070360
16.

[Advantages and risks of the use of prostate-specific antigen (PSA) in the health-care area No. 4 of Gijon (Asturias)].

Cepeda Piorno J, Rivas del Fresno M, Fuente Martín E, González García E, Muruamendiaraz Fernández V, Fernández Rodríguez E.

Arch Esp Urol. 2005 Jun;58(5):403-11. Spanish.

PMID:
16078781
17.

Incidence of insignificant prostate cancer using free/total PSA: results of a case-finding protocol on 14,453 patients.

Pepe P, Aragona F.

Prostate Cancer Prostatic Dis. 2010 Dec;13(4):316-9. doi: 10.1038/pcan.2010.29. Epub 2010 Aug 17.

PMID:
20714341
19.

Supplemental Content

Support Center